Advertisement

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Deborah Collyar: What's In It for Patients?

Peter Clark, MA, MD, FRCP: A Payer Perspective

Advertisement

Advertisement

Nov

04

Today In Oncology

Basser Center for BRCA Awards 2026 Global Prize

Triplet Therapy With Abiraterone Improves OS Long-Term in Metastatic Castration-Sensitive Prostate Cancer

Phase III VOLGA Trial Explores Outcomes in Muscle Invasive Bladder Cancer

First-Line Pembrolizumab Improves Progression-Free Survival in dMMR Advanced Endometrial Cancer

Bispecific ADC May Offer New Treatment Option for HR-Positive, HER2-Negative Breast Cancer

Advertisement

© 2026 HSP News Service, L.L.C.